Skip to main content

Molecular Medicine

Featured Article: Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?

In this review article, the authors discuss the potential for extracellular HMGB1 as a target for treating COVID-19.

New Content Item (1)

Call for Papers: Preparing for the next pandemic: a molecular medicine approach

Edited by

Douglas Nixon, Weill Cornell Medical College, USA
Johan Sandberg , Karolinska Institute, Sweden

New Content Item

Call for Papers: Parkinson's disease as a circuit disorder: Advances from a network perspective

Edited by
Katharina A. Schindlbeck, The Feinstein Institutes for Medical Research, USA
Martin H. Niethammer, The Feinstein Institutes for Medical Research, USA
 

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

Aims and scope

Molecular Medicine is an open access journal publishing recent findings that elucidate disease pathogenesis at the molecular or physiological level, which may lead to the design of specific tools for disease diagnosis, treatment, or prevention. Manuscripts containing material relevant to the genetic, molecular, or cellular basis of key physiologic or disease processes are considered for publication. Manuscripts submitted to Molecular Medicine should describe the implications of the results for human disease and medicine, at a level approachable by our broad audience.

Criteria to consider for studies involving lnc-RNAs or micro-RNAs:

·        As lncRNAs and miRNAs have multiple targets, claims of their function mediated by a single target or pathway will not be accepted, unless multiple additional targets are investigated to support functional specificity.

·        The rationale to investigate a specific lncRNA or miRNA needs to be specified upfront in the introduction and justified in the context of other miRNAs known to be functional in that specific field.

·        The proposed function of the lnc-RNA or miRNA should be validated by gain and loss of function studies.

·        Primary cells should be used whenever possible to confirm findings in cell lines.

·        In depth investigation in the signaling pathway(s) regulated by the RNA species should be conducted.

·        Insight into the regulation of the RNA species and how it relates to the pathologic state should be provided.

·        If applicable: Details of initial screen used to identify RNA species involvement in pathway/disease (number of subjects, statistical tests employed, percent change from controls).

Nobel congratulations to William G. Kaelin Jr

New Content ItemMolecular Medicine is happy to congratulate William G. Kaelin Jr on being a winner of The Nobel Prize in Physiology or Medicine 2019. Professor Kaelin Jr was chosen for his work on the discoveries of how cells sense and adapt to oxygen availability. He previously contributed an article to our journal, "The Molecular Basis of Von Hippel-Lindau Disease", which you can read here.


Articles

Most recent articles RSS

View all articles

Most accessed articles RSS

View all articles

Top 10: Most Cited Articles of 2019 and 2020

Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?
Ulf Andersson, William Ottestad, & Kevin J. Tracey  

IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19
Yu Chen et al.

LncRNA PVT1 regulates atrial fibrosis via miR-128-3p-SP1-TGF-β1-Smad axis in atrial fibrillation 
Feng Cao, Zhe Li, Wen-mao Ding, Ling Yan, & Qing-yan Zhao 

Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation
Huan Yang et al. 

Gut microbiota promote the inflammatory response in the pathogenesis of systemic lupus erythematosus
Yiyangzi Ma, Xiaoxue Xu, Mengtao Li, Jun Cai, Qiang Wei, & Haitao Niu 

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
Alexander P. de Porto et al. 

miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease
Jun-Ke Long, Wen Dai, Ya-Wen Zheng, & Shui-Ping Zhao 

Post-sepsis syndrome – an evolving entity that afflicts survivors of sepsis
Zachary Mostel et al.

The neuroprotective mechanisms of ginkgolides and bilobalide in cerebral ischemic injury: a literature review
Zili Feng, Qian Sun, Wang Chen, Yu Bai, Daihua Hu, & Xin Xie 

Electroacupuncture attenuated cerebral ischemic injury and neuroinflammation through α7nAChR-mediated inhibition of NLRP3 inflammasome in stroke rats
Tao Jiang et al. 

Featured cross-journal series: Molecular mechanisms and therapeutic relevance of neuro-immune communication

New Content ItemOur new cross-journal thematic series (published in conjunction with Bioelectronic Medicine), calls for submissions focusing on the molecular mechanisms and therapeutic exploration at the interface between the immune and nervous systems in health and disease and the therapeutic exploration of this insight. It will also cover emerging areas such as the neuronal regulation of hematopoiesis and innate and adaptive immunity. The series is guest edited by Sangeeta Chavan, Colin Reardon, and Niccolò Terrando. Find more information here. 

Do you have an idea for a thematic series? Let us know!

New Content Item

Announcing our new article types

Our journal is proud to offer four new article types, ready for submissions! 

  • Mini-reviews, which provide a concise summary of a specific research topic or field relevant to our scope
  • Perspectives, which grants the opportunity to write about the current state and recent developments of a research field or topic within our scope and point to associated challenges and future directions
  • Opinions, written with a specific focus on a previously published article which has had a major impact on the field.
  • Commentaries, invited pieces which provide further discussion on a primary research manuscript. 

Please see our Submission Guidelines page for more.

New Content Item

Reviewers of the quarter

Molecular Medicine would like to recognize the efforts of the exceptional peer reviewers, for their excellent service. This individual has exceeded expectations as far as acceptance rate, the number of completed reviews, and timeliness, during the third quarter of 2020. The journal cannot succeed without its peer reviewers, and we thank the hard-working members of our network.


Dr. Louise A. Johnson



About the Editors

​​​​​New Content ItemDr Betty Diamond (Editor-in-Chief) graduated with a BA from Harvard University and an MD from Harvard Medical School. She performed a residency in Internal Medicine at Columbia Presbyterian Medical Center and received postdoctoral training in immunology at the Albert Einstein College of Medicine.

Dr Diamond has headed the Rheumatology Divisions at Albert Einstein School of Medicine and at Columbia University Medical Center. She also directed the Medical Scientist Training Program at Albert Einstein School of Medicine for many years. She is currently head of the Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases at The Feinstein Institutes for Medical Research and Director of the PhD and MD/PhD programs at the Zucker School of Medicine at Hofstra-Northwell.

A past president of the American Association of Immunology, Dr Diamond has also served on the Board of Directors of the American College of Rheumatology and the Scientific Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

Dr Diamond is a Fellow of the American Association for the Advancement of Science (AAAS) and a member of the National Academy of Medicine.

New Content ItemValentin Pavlov, The Feinstein Institutes for Medical Research, USA- Executive Editor 
 



New Content Item (1)Maria Ruggieri, The Feinstein Institutes for Medical Research, USA- Managing Editor

 


New Content ItemSonya VanPatten, The Feinstein Institutes for Medical Research, USA- Coordinating Editor


Awards

Anthony Cerami Award in Translational Medicine
Molecular Medicine has established the Anthony Cerami Award in Translational Medicine to honor investigators who have created the fundamental innovation necessary for molecular medicine to advance into clinical practice.  The award recognizes leading edge discoveries that have led to improvement of human health, and have opened the door to new therapeutic advances and understanding. Find out more.

Ross Prize in Molecular Medicine
The annual Ross Prize in Molecular Medicine is established in conjunction with the Feinstein Institutes for Medical Research and Molecular Medicine. The winner will be an active investigator having produced innovative, paradigm-shifting research that is worthy of significant and broad attention in the field of molecular medicine. Find out more.

Message from the Editors

The Feinstein Institutes Editorial Team and BMC Rejuvenate Molecular Medicine - 30 July 2018

What happens when the immune system goes rogue?

In her 2017 TEDMED Talk, Editor-in-Chief Dr Betty Diamond discusses the latest insights in autoimmune disease research, and the pivotal role that patients play in studies.

Pre-submission inquiries

The Editors of Molecular Medicine welcome authors to send any pre-submission inquiries they might have, here. We ask that you please include “Pre-submission inquiry” in the subject line of your email and that you include the title and abstract of your proposed submission within the message. Our Editors will do their best to respond to you in a timely manner.

Bioelectronic Medicine

New Content ItemIf you enjoy Molecular Medicine, we invite you to visit Feinstein’s Bioelectronic Medicine (published by BMC). Bioelectronic Medicine focuses on the regulatory functions of the nervous system and technologies that record, stimulate, or block neural signaling to affect specific molecular mechanisms in health and disease. It also features bioelectronic approaches for monitoring and controlling biological processes and for providing insights into disease pathogenesis that can be utilized in new treatments of inflammatory, neurodegenerative, gastrointestinal, and cardiovascular diseases, paralysis, and many other conditions.

About Feinstein Institutes for Medical Research

New Content ItemMolecular Medicine is published in partnership with The Feinstein Institutes for Medical Research. As the research arm of Northwell Health, the largest healthcare provider in New York, it is home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities. The Feinstein Institutes include 4,000 researchers and staff who are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how the Feinstein Institutes empower imagination and pioneers discovery, visit FeinsteinInstitute.org.

Submit manuscript

Annual Journal Metrics

  • Speed
    43 days to first decision for reviewed manuscripts only
    28 days to first decision for all manuscripts
    128 days from submission to acceptance
    24 days from acceptance to publication


    Citation Impact
    6.354 - 2-year Impact Factor
    5.230 - 5-year Impact Factor

    Usage
    460,369 downloads
    204 Altmetric mentions

Follow

Molecular Medicine

ISSN: 1528-3658